Literature DB >> 29926735

Short Communication: Assessing Estimates of HIV Incidence with a Recent Infection Testing Algorithm That Includes Viral Load Testing and Exposure to Antiretroviral Therapy.

Andrea A Kim1, Thomas Rehle2.   

Abstract

A recent infection testing algorithm (RITA) that includes a test for recent HIV infection and a viral load (VL) test is the recommended strategy to estimate national HIV incidence, reducing false-recent misclassification to <1%. The inclusion of information on exposure to antiretroviral therapy (ART), as a supplement to VL testing, could improve RITA performance by further lowering false-recent misclassification of true long-term infection. In 2012, Kenya and South Africa conducted national population-based surveys that collected information on HIV recency (i.e., HIV antibody seroconversion, on average, in the past 130 days) using the Limiting Antigen avidity (LAg-Avidity) enzyme immunoassay, HIV RNA levels, and ART exposure among HIV-infected respondents aged 15-49 years. In Kenya, ART exposure was defined as testing positive for one or more antiretroviral (ARV) drugs using high-performance liquid chromatography coupled with tandem mass spectrometry, and, if not ARV-positive, self-reporting a history of ART exposure. In South Africa, ART exposure was defined as testing ARV-positive. Two RITA strategies were compared: RITA #1 defined recent infection as testing LAg-Avidity-recent with unsuppressed VL (HIV RNA ≥1,000 copies/ml), and RITA #2 defined recent infection as testing LAg-Avidity-recent with unsuppressed VL and, if unsuppressed, having no ART exposure. RITA-derived incidence among persons aged 15-49 years in Kenya was 0.9% on RITA #1 and 0.8% on RITA #2. In South Africa, RITA-derived incidence was 2.2% on RITA #1 and 1.7% on RITA #2. Among specimens testing recent with unsuppressed VL in Kenya and South Africa, 16.0% and 19.7% had evidence of ART exposure, respectively. Although the performance of a VL- and ART-based RITA was encouraging, additional research is needed across HIV-1 subtypes and subpopulations to calibrate and validate this algorithm.

Entities:  

Keywords:  HIV incidence; Limiting Antigen avidity enzyme immunoassay; national population-based survey; recent infection testing algorithm; sub-Saharan Africa

Mesh:

Substances:

Year:  2018        PMID: 29926735     DOI: 10.1089/AID.2017.0316

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  8 in total

1.  Decreased Seroreactivity in Individuals Initiating Antiretroviral Therapy during Acute HIV Infection.

Authors:  Mark M Manak; Linda L Jagodzinski; Ashley Shutt; Jennifer A Malia; Mike Leos; Jason Ouellette; Siriwat Akapirat; Donn L Colby; Nittaya Phanuphak; Leigh Anne Eller; Merlin L Robb; Mark de Souza; Jintanat Ananworanich; Sheila A Peel
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

2.  Impact of Early Antiretroviral Treatment Initiation on Performance of Cross-Sectional Incidence Assays.

Authors:  Ethan Klock; George Mwinnya; Leigh Anne Eller; Reinaldo E Fernandez; Hannah Kibuuka; Sorachai Nitayaphan; Josphat Kosgei; Richard D Moore; Merlin Robb; Susan H Eshleman; Oliver Laeyendecker
Journal:  AIDS Res Hum Retroviruses       Date:  2020-05-27       Impact factor: 2.205

3.  Microdrop Human Immunodeficiency Virus Sequencing for Incidence and Drug Resistance Surveillance.

Authors:  Sung Yong Park; Gina Faraci; Gary Murphy; Christopher Pilcher; Michael P Busch; Ha Youn Lee
Journal:  J Infect Dis       Date:  2021-09-17       Impact factor: 5.226

4.  Can HIV recent infection surveillance help us better understand where primary prevention efforts should be targeted? Results of three pilots integrating a recent infection testing algorithm into routine programme activities in Kenya and Zimbabwe.

Authors:  Brian D Rice; Mariken de Wit; Susie Welty; Kathryn Risher; Frances M Cowan; Gary Murphy; Sungai T Chabata; Wanjiru Waruiru; Sitholubuhle Magutshwa; John Motoku; Daniel Kwaro; Benard Ochieng; Georges Reniers; George Rutherford
Journal:  J Int AIDS Soc       Date:  2020-06       Impact factor: 5.396

5.  HIV-1 Recent Infection Testing Algorithm With Antiretroviral Drug Detection to Improve Accuracy of Incidence Estimates.

Authors:  Andrew C Voetsch; Yen T Duong; Paul Stupp; Suzue Saito; Stephen McCracken; Trudy Dobbs; Frieda S Winterhalter; Daniel B Williams; Assegid Mengistu; Owen Mugurungi; Prisca Chikwanda; Godfrey Musuka; Clement B Ndongmo; Sindisiwe Dlamini; Harriet Nuwagaba-Biribonwoha; Munyaradzi Pasipamire; Belete Tegbaru; Frehywot Eshetu; Samuel Biraro; Jennifer Ward; Dorothy Aibo; Andrew Kabala; George S Mgomella; Optatus Malewo; Jeremiah Mushi; Danielle Payne; Yohannes Mengistu; Fred Asiimwe; Judith D Shang; Emily K Dokubo; Laura T Eno; Anne-Cécile Zoung-Kanyi Bissek; Leonard Kingwara; Muthoni Junghae; John N Kiiru; Richard C N Mwesigwa; Shirish Balachandra; Roger Lobognon; Elizabeth Kampira; Mervi Detorio; Ernest L Yufenyuy; Kristin Brown; Hetal K Patel; Bharat S Parekh
Journal:  J Acquir Immune Defic Syndr       Date:  2021-08-01       Impact factor: 3.771

6.  Development of an international external quality assurance program for HIV-1 incidence using the Limiting Antigen Avidity assay.

Authors:  Sheila M Keating; Wes Rountree; Eduard Grebe; Andrea L Pappas; Mars Stone; Dylan Hampton; Christopher A Todd; Marek S Poniewierski; Ana Sanchez; Cassandra G Porth; Thomas N Denny; Michael P Busch
Journal:  PLoS One       Date:  2019-09-16       Impact factor: 3.240

Review 7.  Use of HIV Recency Assays for HIV Incidence Estimation and Other Surveillance Use Cases: Systematic Review.

Authors:  Shelley N Facente; Eduard Grebe; Andrew D Maher; Douglas Fox; Susan Scheer; Mary Mahy; Shona Dalal; David Lowrance; Kimberly Marsh
Journal:  JMIR Public Health Surveill       Date:  2022-03-11

8.  Inferring population HIV incidence trends from surveillance data of recent HIV infection among HIV testing clients.

Authors:  Arnaud Godin; Jeffrey W Eaton; Katia Giguère; Kimberly Marsh; Leigh F Johnson; Andreas Jahn; Francisco Mbofana; Eboi Ehui; Mathieu Maheu-Giroux
Journal:  AIDS       Date:  2021-11-15       Impact factor: 4.177

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.